Étiquette : essai clinique

Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis, Chad Purcell,

Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis Chad Purcell, Andrew Davis, Nico Moolman, and S. Mark Taylor Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, Doi : 10.1089/can.2018.0020   Abstract Background : Benzodiazepines are a class of medication with sedative properties, commonly used for anxiety and other neurological conditions. These medications are associated with several well-known adverse effects. This observational study aims to investigate the reduction of benzodiazepine use in patients using prescribed medical cannabis. Methods : A retrospective analysis was performed on a cohort of 146 medical cannabis patients (average age 47 years, 61% female, 54% reporting prior use of cannabis) who reported [...]

Lire la suite

FDA Okays New Indication for Esketamine Nasal Spray, Megan Brooks, Medscape – Aug 03, 2020.

FDA Okays New Indication for Esketamine Nasal Spray Megan Brooks Medscape - Aug 03, 2020. The US Food and Drug Administration (FDA) has approved the supplemental new drug application for esketamine nasal spray (Spravato, Janssen Pharmaceuticals) to treat depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. The FDA approved esketamine nasal spray for treatment-resistant depression in March 2019, as reported by Medscape Medical News. The new indication is based on data from two identical phase 3 trials — ASPIRE I and ASPIRE II — which evaluated the efficacy and safety of the nasal spray in addition to a comprehensive standard of care [...]

Lire la suite

Cannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial, Tom P. Freeman et al., 2020

Cannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial Tom P Freeman, Chandni Hindocha, Gianluca Baio, Natacha D C Shaban, Emily M Thomas, Danica Astbury, Abigail M Freeman, Rachel Lees, Sam Craft, Paul D Morrison, Michael A P Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia J A Morgan, Ali Mofeez, H Valerie Curran The Lancet Psychiatry, 2020, doi : 10.1016/S2215-0366(20)30290-X  Abstract Background : A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using [...]

Lire la suite

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers, Johannes G. Ramaekers et al., 2020,

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers Johannes G. Ramaekers, Nadia Hutten, Natasha L. Mason, Patrick Dolder1, Eef L. Theunissen, Friederike Holze, Matthias E. Liechti, Amanda Feilding and Kim P.C. Kuypers Journal of Psychopharmacology, 2020, 1–8. doi : 10.1177/026988112094093   Abstract Background : Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim : The present [...]

Lire la suite

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial, Daryl Efron et al.,

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial Daryl Efron, Kaitlyn Taylor, Jonathan M Payne, Jeremy L Freeman, Noel Cranswick, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Katrina Williams BMJ Open, 2020, 10, e034362. doi : 10.1136/bmjopen-2019-034362   Abstract Introduction : Severe behavioural problems (SBPs) are a common contributor to morbidity and reduced quality of life in children with intellectual disability (ID). Current medication treatment for SBP is associated with a high risk of side effects. Innovative and safe interventions are urgently needed. Anecdotal reports and preliminary research suggest that medicinal [...]

Lire la suite

A Pilot Randomised Placebo-Controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents With Intellectual Disability, Daryl Efron et al., 2020

  A Pilot Randomised Placebo-Controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents With Intellectual Disability Daryl Efron, Jeremy L Freeman, Noel Cranswick, Jonathan M Payne, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Kaitlyn Taylor, Katrina Williams British Journal of Clinical Pharmacology, 2020 Jun 1. doi : 10.1111/bcp.14399. Abstract Introduction : Severe Behavioural Problems (SBP) are a major contributor to morbidity in children with Intellectual Disability (ID). Medications used to treat SBP in ID are associated with a high risk of side effects. Cannabidiol has potential therapeutic effects in SBP. This pilot study aimed to investigate the feasibility of conducting a randomized placebo-controlled [...]

Lire la suite

The Therapeutic Effectiveness of Full Spectrum Hemp Oil Using a Chronic Neuropathic Pain Model, Jacob M. Vigil et al., 2020

The Therapeutic Effectiveness of Full Spectrum Hemp Oil Using a Chronic Neuropathic Pain Model Jacob M. Vigil, Marena A. Montera, Nathan S. Pentkowski, Jegason P. Diviant, Joaquin Orozco, Anthony L. Ortiz, Lawrence J. Rael  and Karin N. Westlund Life, 2020, 10, 69, 1-12 doi : 10.3390/life10050069   Abstract : Background : Few models exist that can control for placebo and expectancy effects commonly observed in clinical trials measuring ‘Cannabis’ pharmacodynamics. We used the Foramen Rotundum Inflammatory Constriction Trigeminal Infraorbital Nerve injury (FRICT-ION) model to measure the effect of “full-spectrum” whole plant extracted hemp oil on chronic neuropathic pain sensitivity in mice. Methods : Male BALBc mice were [...]

Lire la suite

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson’s disease, Isabel Espadas et al., 2020

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease Isabel Espadas, Ettel Keifman, Cristina Palomo-Garo Sonia Burgaz, Concepción García, Javier Fernández-Ruiz, Rosario Moratalla Neurobiology of Disease, 2020, 141, 104892 doi : 10.1016/j.nbd.2020.104892   A B S T R A C T The antioxidant and CB2 receptor agonist properties of Δ9-tetrahydrocannabivarin (Δ9-THCV) afforded neuroprotection in experimental Parkinson's disease (PD), whereas its CB1 receptor antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. In the present study, we investigated the anti dyskinetic potential of Δ9-THCV (administered i.p. at 2 mg/kg for two weeks), which had not been investigated before. This objective was investigated [...]

Lire la suite

Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva, Barbara Broers et al., 2019

Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva Barbara Broers, Zacharie Patà, Aline Mina, James Wampfler, Christian de Saussure, Sophie Pautex Medical Cannabis & Cannabinoids, 2019, 2, 56–59 Doi : 10.1159/000498924 Abstract Background : Dementia is increasing worldwide. No effective medication is currently available for the treatment of the underlying disease and accompanying behavioral symptoms. Cannabinoids might have a beneficial effect, but clinical studies with (low-dose) synthetic THC have not been conclusive. Objective : To test the acceptability, practical aspects, and clinical outcomes of the introduction of a THC/ CBD-based oral medication in severely demented patients in a specialized [...]

Lire la suite

Effet d’entourage contre douleur neuropathique, PrincipesActifs.org, 22 Mai 2020

Effet d’entourage contre douleur neuropathique Publié le 22 Mai 2020 https://www.principesactifs.org/effet-dentourage-contre-douleur-neuropathique/     Cette huile de cannabidiol est efficace contre la douleur neuropathique chronique, conclut cette étude pré-clinique de l’University of New Mexico (UNM). L’étude présentée dans la revue Life suggère que l’huile permet de diviser par 10 la sensibilité à la douleur mécanique et pendant plusieurs heures. Ici chez la souris modèle de douleur neuropathique postopératoire chronique. Ces données présentées dans la revue Life illustrent ce que les experts nomment l’effet d’entourage ou l’action synergique de différents composés du cannabis qui apporte cet effet thérapeutique. Dans cette expérience, il s’agit d’une huile de cannabis contenant [...]

Lire la suite